Returns of unwanted gifts are getting so expensive for retailers that increasingly their answer is: Keep it! We'll give you the refund anyway.

• The return of a $50 item is expected to cost merchants an average of $33 this season, up 59% from 2020, returns processor Optoro tells Axios' Nathan Bomey, soon to be of Axios Closer fame.

Three in 10 online purchases are returned, according to CBRE Supply Chain.

• Returns are often discarded, donated or repurposed for sale through alternate channels.
• That's why some retailers, notably Amazon, are taking the "keep it" approach — because the return would cost too much to process, Optoro CEO Tobin Moore tells Axios.

But don’t try to game the system to get free stuff.

• Retailers keep tabs on frequent returners. Some even keep a "risk score" on customers.

What's next: A rising number of shoppers are returning goods bought online to physical stores, The Wall Street Journal reports.

• Retailers are encouraging it — so they can "make returned products quickly available for resale to offset supply-chain snarls and adjust to rising e-commerce sales."

Share this story.

1. The CDC slashed its estimate of Omicron case prevalence after it ultimately discovered fewer cases as more data came in. Go deeper.
2. The NBA is cutting COVID isolations from 10 to 6 days, as long as people are asymptomatic and meet other testing requirements. Go deeper.
3. The CDC is actively investigating or observing 86 cruise ships following COVID outbreaks on board. Go deeper.
4. Drug regulators in India authorized two COVID vaccines, Corbevax and Covovax, for emergency use. Go deeper.

The rollout of COVID vaccines and a larger, younger crowd willing to try Botox injections have led to swelling demand in dermatology offices and medical spas, reports Axios' Bob Herman.

• Influencers promoting Botox and other cosmetic procedures on TikTok and Instagram and new Botox ads have attracted more people.

Between the lines: Patients getting Botox are now younger on average. "And by younger I mean closer to 40 versus 50," said Carrie Strom, a senior VP at AbbVie, which owns the company that makes Botox.